KDMN - Kadmon Holdings, Inc.

NYSE - NYSE Delayed Price. Currency in USD
2.6200
-0.0300 (-1.13%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close2.6500
Open2.7100
Bid2.6000 x 1000
Ask0.0000 x 900
Day's Range2.5850 - 2.7100
52 Week Range1.6300 - 4.3900
Volume491,007
Avg. Volume928,706
Market Cap339.644M
Beta (3Y Monthly)2.14
PE Ratio (TTM)N/A
EPS (TTM)-0.3720
Earnings DateAug 5, 2019 - Aug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.22
Trade prices are not sourced from all markets
  • Kadmon (KDMN) Completes Enrollment in KD025 Study for cGVHD
    Zacks

    Kadmon (KDMN) Completes Enrollment in KD025 Study for cGVHD

    Kadmon Holdings (KDMN) completes enrollment in the study of its pipeline candidate, KD025, for the treatment of chronic graft-versus-host disease (cGVHD).

  • ACCESSWIRE

    Kadmon Fully Enrolls Pivotal Trial of KD025 for Chronic Graft-Versus-Host Disease

    NEW YORK, NY / ACCESSWIRE / August 13, 2019 / Kadmon Holdings, Inc. (KDMN) today announced that KD025-213, an open-label registration trial of KD025 for the treatment of chronic graft-versus-host disease (cGVHD), is fully enrolled. The study is being conducted at more than 30 clinical sites throughout the United States. The Company expects to disclose outcomes from a planned interim analysis before year end.

  • ACCESSWIRE

    Kadmon Provides Business Update and Reports Second Quarter 2019 Financial Results

    NEW YORK, NY / ACCESSWIRE / August 5, 2019 / Kadmon Holdings, Inc. (NYSE: KDMN) today provided a business update and reported financial and operational results for the second quarter of 2019. “We have ...

  • Will Kadmon Holdings (KDMN) Report Negative Q2 Earnings? What You Should Know
    Zacks

    Will Kadmon Holdings (KDMN) Report Negative Q2 Earnings? What You Should Know

    Kadmon Holdings (KDMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • If You Had Bought Kadmon Holdings (NYSE:KDMN) Stock A Year Ago, You'd Be Sitting On A 22% Loss, Today
    Simply Wall St.

    If You Had Bought Kadmon Holdings (NYSE:KDMN) Stock A Year Ago, You'd Be Sitting On A 22% Loss, Today

    Kadmon Holdings, Inc. (NYSE:KDMN) shareholders will doubtless be very grateful to see the share price up 50% in the...

  • Moleculin Files New Patents for Cancer Candidate Annamycin
    Zacks

    Moleculin Files New Patents for Cancer Candidate Annamycin

    Moleculin (MBRX) petitions for new patents to cover annamycin, currently being developed for treating patients with relapsed or refractory acute myeloid leukemia. Shares rise.

  • Kadmon Initiates Dosing in Study for Systemic Sclerosis Drug
    Zacks

    Kadmon Initiates Dosing in Study for Systemic Sclerosis Drug

    Kadmon (KDMN) doses first patient in a phase II study of KD025 for the treatment of diffuse cutaneous systemic sclerosis (SSc).

  • ACCESSWIRE

    Kadmon Doses First Patient in Phase 2 Clinical Trial of KD025 in Systemic Sclerosis

    NEW YORK, NY / ACCESSWIRE / July 9, 2019 / Kadmon Holdings, Inc. (KDMN) today announced that the first patient has been dosed in a Phase 2 clinical trial of KD025, the Company’s ROCK2 inhibitor, in patients with diffuse cutaneous systemic sclerosis (SSc). SSc is a chronic immune disorder characterized by fibrosis of the skin and internal organs, affecting approximately 75,000 to 100,000 people in the United States. The double-blind, placebo-controlled Phase 2 study (KD025-209) will randomize 60 adults with SSc to receive KD025 200 mg QD, KD025 200 mg BID or placebo (20 per arm) for 24 weeks, followed by an open-label extension period to allow treatment for up to 52 weeks.

  • Hedge Funds Have Never Been This Bullish On Kadmon Holdings, Inc. (KDMN)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Kadmon Holdings, Inc. (KDMN)

    How do we determine whether Kadmon Holdings, Inc. (NYSE:KDMN) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows […]

  • ACCESSWIRE

    Kadmon to Present at the Jefferies 2019 Global Healthcare Conference

    NEW YORK, NY / ACCESSWIRE / May 29, 2019 / Kadmon Holdings, Inc. (NYSE: KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the Jefferies 2019 Global ...

  • How Many Kadmon Holdings, Inc. (NYSE:KDMN) Shares Do Institutions Own?
    Simply Wall St.

    How Many Kadmon Holdings, Inc. (NYSE:KDMN) Shares Do Institutions Own?

    Every investor in Kadmon Holdings, Inc. (NYSE:KDMN) should be aware of the most powerful shareholder groups. Large...

  • ACCESSWIRE

    Kadmon Provides Business Update and Reports First Quarter 2019 Financial Results

    NEW YORK, NY / ACCESSWIRE / May 9, 2019 / Kadmon Holdings, Inc. (NYSE: KDMN) today provided a business update and reported financial and operational results for the first quarter of 2019. ''The advancement ...

  • ACCESSWIRE

    Kadmon to Present at the H.C. Wainwright Global Life Sciences Conference

    NEW YORK, NY / ACCESSWIRE / April 3, 2019 / Kadmon Holdings, Inc. (NYSE: KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the H.C. Wainwright Global ...

  • ACCESSWIRE

    Kadmon Announces Appointment of Arthur Kirsch to Board of Directors

    NEW YORK, NY / ACCESSWIRE / April 1, 2019 / Kadmon Holdings, Inc. (KDMN) today announced that Arthur Kirsch has been nominated to stand for election to Kadmon's Board of Directors at the upcoming annual meeting of shareholders on May 15, 2019. Mr. Kirsch has more than 40 years of experience leading global healthcare research and investment banking operations and also serves on the boards of several emerging biopharmaceutical companies. "Arthur is a prominent and well-respected figure in the healthcare industry.

  • ACCESSWIRE

    Kadmon Announces Susan Wiviott to Step Down from Board of Directors

    NEW YORK, NY / ACCESSWIRE / March 22, 2019 / Kadmon Holdings, Inc. (KDMN) today announced that Susan Wiviott does not intend to stand for re-election to Kadmon's Board of Directors at the upcoming annual meeting of shareholders on May 15, 2019 (the "Annual Meeting"). On March 21, 2019, Ms. Wiviott provided notice to the Company of her intent to resign effective as of the Annual Meeting, and confirmed that her intent to not stand for re-election is not because of any disagreement between her and the Company. "Susan has served on our Board since the Company's earliest stages and we are fortunate to have had the benefit of her counsel over the years," said Harlan W. Waksal, M.D., President and CEO at Kadmon.

  • When Will Kadmon Holdings, Inc. (NYSE:KDMN) Become Profitable?
    Simply Wall St.

    When Will Kadmon Holdings, Inc. (NYSE:KDMN) Become Profitable?

    Kadmon Holdings, Inc.'s (NYSE:KDMN): Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The US$379m market-capRead More...

  • ACCESSWIRE

    Kadmon to Present at the Oppenheimer 29th Annual Healthcare Conference

    NEW YORK, NY / ACCESSWIRE / March 13, 2019 / Kadmon Holdings, Inc. (NYSE: KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at Oppenheimer's 29 th Annual ...

  • ACCESSWIRE

    Kadmon Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results

    NEW YORK, NY / ACCESSWIRE / March 7, 2019 / Kadmon Holdings, Inc. (NYSE: KDMN) today provided a business update and reported financial and operational results for the fourth quarter and full year ended ...

  • GlobeNewswire

    Kadmon Announces Appointment of Steven Meehan as CFO

    Kadmon Holdings, Inc. (KDMN) today announced the appointment of Steven Meehan as Executive Vice President, Chief Financial Officer. Mr. Meehan will provide strategic leadership to Kadmon’s finance organization and will assume responsibility for the Company’s internal controls and business processes.

  • GlobeNewswire

    Kadmon Announces Appointment of David E. Cohen, M.D., MPH, to Board of Directors

    Kadmon Holdings, Inc. (KDMN) today announced the appointment of David E. Cohen, M.D., MPH, to its Board of Directors. Dr. Cohen has held a variety of positions at the New York University School of Medicine, including as Chief of Allergy and Contact Dermatitis, Vice Chairman of Clinical Affairs, Director of Occupational and Environmental Dermatology, and the Charles C. and Dorothea E. Harris Professor of Dermatology. “David brings to Kadmon a deep understanding of the research and treatment of immune and fibrotic disorders, which aligns perfectly with our near-term focus to bring promising new products to market in these therapeutic areas,” said Harlan W. Waksal, M.D., President and CEO at Kadmon.

  • GlobeNewswire

    New Research: Key Drivers of Growth for Real Goods Solar, Standard Motor Products, Progress Software, Avon Products, Natus Medical, and Kadmon — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Jan. 28, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire

    Kadmon Announces Appointment of Cynthia Schwalm to Board of Directors

    Kadmon Holdings, Inc. (KDMN) today announced the appointment of Cynthia Schwalm to its Board of Directors. “Cynthia is an accomplished pharmaceutical executive who brings strong cross-functional operational and commercialization expertise to Kadmon,” said Harlan W. Waksal, M.D., President and CEO at Kadmon. “Cynthia has a demonstrated track record of cultivating successful businesses and implementing tactical changes to drive transformative growth.

  • GlobeNewswire

    Kadmon Announces Appointment of Tasos G. Konidaris as Interim Chairman of the Board

    Kadmon Holdings, Inc. (KDMN) today announced that Tasos G. Konidaris, a member of Kadmon’s board of directors, has been appointed interim chairman, effective immediately. Mr. Konidaris has significant experience in the biotechnology industry, including serving as Executive Vice President and Chief Financial Officer of Alcresta Therapeutics, Inc. since March 2016 and as a senior advisor of Athyrium Capital Management, L.P. since September 2015. Previously, Mr. Konidaris held senior financial and operational roles at Ikaria, Dun & Bradstreet, Schering-Plough, Pharmacia, Rhone-Poulenc Rorer, Novartis and Bristol-Myers Squibb.

  • GlobeNewswire

    Kadmon Chairman Bart M. Schwartz to Step Down from Board

    Kadmon Holdings, Inc. (KDMN) today announced that Bart M. Schwartz, Esq. Kadmon’s Board will identify a new chairman as part of its ongoing process to refresh the composition of the Board. A nationally recognized executive search firm is assisting in this search process.

  • GlobeNewswire

    Kadmon Announces Updated Findings from Ongoing Phase 2 Clinical Trial of KD025 in cGVHD at ASH Annual Meeting

    NEW YORK, Dec. 03, 2018 -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced updated data from its ongoing Phase 2 clinical trial of KD025, its selective oral inhibitor of.